A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Study completion date changed from estimate of Aug 2026 to Sep 14, 2026
    • Site details revised at 3 of 52 sites
    • Eligibility criteria expanded, about 3 words
  2. Enrollment target: estimated 350 to confirmed 367
    • Primary completion date changed from estimate of Jun 2026 to Jul 1, 2026
    v14
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 52 of 52 sites
    v13
  4. Site details revised at 45 of 52 sitesv12
  5. Site contacts updated at 1 of 52 sitesv11
Show 9 earlier versionsHide 9 earlier versions
  1. 2 versions Re-verified since May 23, 2025, no change to tracked fieldsv9-v10
  2. Study sites: 51 to 52v8
  3. Site details revised at 2 of 51 sitesv7
  4. Re-verified, no change to tracked fieldsv6
  5. Study sites: 48 to 51v5
  6. Study sites: 10 to 48v4
  7. Study Status, Referencesv3
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 10
    • Start date changed from estimate of Oct 2024 to Sep 20, 2024
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
363 trials monitored
See 16 trials at risk
Diabetes
5,101 trials monitored
See 233 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Type 2 Diabetes
2,236 trials monitored
See 113 trials at risk
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.
Trial Details
NCT Number NCT06603571
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Obesity, Overweight
Related terms Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 367 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov